Divya Madhu, PharmD

Telix Pharmaceuticals
New York, NY

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 3278 - A Phase 2/3 Study of ¹⁷⁷Lu-TLX591 Plus SOC vs. SOC Alone in Patients with Metastatic Castration-Resistant Prostate Cancer (ProstACT GLOBAL)

  Tuesday, October 1, 2024
  2:30 PM – 3:45 PM ET